|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Digklia A and Wagner AD: Advanced gastric
cancer: Current treatment landscape and future perspectives. World
J Gastroenterol. 22:2403–2414. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Spolverato G, Ejaz A, Kim Y, Squires MH,
Poultsides GA, Fields RC, Schmidt C, Weber SM, Votanopoulos K,
Maithel SK and Pawlik TM: Rates and patterns of recurrence after
curative intent resection for gastric cancer: A United States
multi-institutional analysis. J Am Coll Surg. 219:664–675. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Belletti B and Baldassarre G: Stathmin: A
protein with many tasks. New biomarker and potential target in
cancer. Expert Opin Ther Targets. 15:1249–1266. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hemdan T, Linden M, Lind SB, Namuduri AV,
Sjöstedt E, de Ståhl TD, Asplund A, Malmström PU and Segersten U:
The prognostic value and therapeutic target role of stathmin-1 in
urinary bladder cancer. Br J Cancer. 111:1180–1187. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shimizu K, Ohtaki Y, Altan B, Yokobori T,
Nagashima T, Arai M, Mogi A and Kuwano H: Prognostic impact of
stathmin 1 expression in patients with lung adenocarcinoma. J
Thorac Cardiovasc Surg. 154:1406–1417.e3. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Suzuki S, Yokobori T, Altan B, Hara K,
Ozawa D, Tanaka N, Sakai M, Sano A, Sohda M, Bao H, et al: High
stathmin 1 expression is associated with poor prognosis and
chemoradiation resistance in esophageal squamous cell carcinoma.
Int J Oncol. Mar 7–2017.(Epub ahead of print). View Article : Google Scholar
|
|
8
|
Tian FJ, Qin CM, Li XC, Wu F, Liu XR, Xu
WM and Lin Y: Decreased stathmin-1 expression inhibits trophoblast
proliferation and invasion and is associated with recurrent
miscarriage. Am J Pathol. 185:2709–2721. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tseng YH, Huang YH, Lin TK, Wu SM, Chi HC,
Tsai CY, Tsai MM, Lin YH, Chang WC, Chang YT, et al: Thyroid
hormone suppresses expression of stathmin and associated tumor
growth in hepatocellular carcinoma. Sci Rep. 6:387562016.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang J, Yao Y, Ming Y, Shen S, Wu N, Liu
J, Liu H, Suo T, Pan H, Zhang D, et al: Downregulation of stathmin
1 in human gallbladder carcinoma inhibits tumor growth in vitro and
in vivo. Sci Rep. 6:288332016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ke B, Wu LL, Liu N, Zhang RP, Wang CL and
Liang H: Overexpression of stathmin 1 is associated with poor
prognosis of patients with gastric cancer. Tumour Biol.
34:3137–3145. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Micalizzi DS, Farabaugh SM and Ford HL:
Epithelial-mesenchymal transition in cancer: Parallels between
normal development and tumor progression. J Mammary Gland Biol
Neoplasia. 15:117–134. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Creighton CJ, Chang JC and Rosen JM:
Epithelial-mesenchymal transition (EMT) in tumor-initiating cells
and its clinical implications in breast cancer. J Mammary Gland
Biol Neoplasia. 15:253–260. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kang Y and Massagué J:
Epithelial-mesenchymal transitions: Twist in development and
metastasis. Cell. 118:277–279. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huang L, Wu RL and Xu AM:
Epithelial-mesenchymal transition in gastric cancer. Am J Transl
Res. 7:2141–2158. 2015.PubMed/NCBI
|
|
17
|
Zhang H, Liu J, Yue D, Gao L, Wang D,
Zhang H and Wang C: Clinical significance of E-cadherin, β-catenin,
vimentin and S100A4 expression in completely resected squamous cell
lung carcinoma. J Clin Pathol. 66:937–945. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li N, Jiang P, Du W, Wu Z, Li C, Qiao M,
Yang X and Wu M: Siva1 suppresses epithelial-mesenchymal transition
and metastasis of tumor cells by inhibiting stathmin and
stabilizing microtubules. Proc Natl Acad Sci USA. 108:12851–12856.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Williams K, Ghosh R, Giridhar PV, Gu G,
Case T, Belcher SM and Kasper S: Inhibition of stathmin1
accelerates the metastatic process. Cancer Res. 72:5407–5417. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu J, Cao J and Zhao X: miR-221
facilitates the TGFbeta1-induced epithelial-mesenchymal transition
in human bladder cancer cells by targeting STMN1. BMC Urol.
15:362015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sobin LH, Gospodarowicz MK and Wittekind
C: TNM Classification of Malignant Tumors. 7th. Wiley-Blackwell;
Oxford: 2010
|
|
22
|
Gao Y, Niu Y, Wang X, Wei L, Zhang R, Lv
S, Yu Q and Yang X: Chromosome aberrations associated with
centrosome defects: A study of comparative genomic hybridization in
breast cancer. Human Pathol. 42:1693–1701. 2011. View Article : Google Scholar
|
|
23
|
Liu Y, Bi T, Dai W, Wang G, Qian L, Shen G
and Gao Q: Lupeol induces apoptosis and cell cycle arrest of human
osteosarcoma cells through PI3K/AKT/mTOR pathway. Technol Cancer
Res Treat. 15:NP16–NP24. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xia P and Xu XY: Epithelial-mesenchymal
transition and gastric cancer stem cell. Tumour Biol.
39:10104283176983732017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Peng Z, Wang CX, Fang EH, Wang GB and Tong
Q: Role of epithelial-mesenchymal transition in gastric cancer
initiation and progression. World J Gastroenterol. 20:5403–5410.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lu Y, Liu C, Xu YF, Cheng H, Shi S, Wu CT
and Yu XJ: Stathmin destabilizing microtubule dynamics promotes
malignant potential in cancer cells by epithelial-mesenchymal
transition. Hepatobiliary Pancreat Dis Int. 13:386–394. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jeon TY, Han ME, Lee YW, Lee YS, Kim GH,
Song GA, Hur GY, Kim JY, Kim HJ, Yoon S, et al: Overexpression of
stathmin1 in the diffuse type of gastric cancer and its roles in
proliferation and migration of gastric cancer cells. Br J Cancer.
102:710–718. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kang W, Tong JH, Chan AW, Lung RW, Chau
SL, Wong QW, Wong N, Yu J, Cheng AS and To KF: Stathmin1 plays
oncogenic role and is a target of microRNA-223 in gastric cancer.
PLoS One. 7:e339192012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
De Wever O, Pauwels P, De Craene B, Sabbah
M, Emami S, Redeuilh G, Gespach C, Bracke M and Berx G: Molecular
and pathological signatures of epithelial-mesenchymal transitions
at the cancer invasion front. Histochem Cell Biol. 130:481–494.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang J, Chen XY, Huang KJ, Wu WD, Jiang
T, Cao J, Zhou LS, Qiu ZJ and Huang C: Expression of FoxM1 and the
EMT-associated protein E-cadherin in gastric cancer and its
clinical significance. Oncol Lett. 12:2445–2450. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Di Bartolomeo M, Pietrantonio F,
Pellegrinelli A, Martinetti A, Mariani L, Daidone MG, Bajetta E,
Pelosi G, de Braud F, Floriani I and Miceli R: Osteopontin,
E-cadherin, and β-catenin expression as prognostic biomarkers in
patients with radically resected gastric cancer. Gastric Cancer.
19:412–420. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu WF, Ji SR, Sun JJ, Zhang Y, Liu ZY,
Liang AB and Zeng HZ: CD146 expression correlates with
epithelial-mesenchymal transition markers and a poor prognosis in
gastric cancer. Int J Mol Sci. 13:6399–6406. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhong XY, Zhang LH, Jia SQ, Shi T, Niu ZJ,
Du H, Zhang GG, Hu Y, Lu AP, Li JY and Ji JF: Positive association
of up-regulated Cripto-1 and down-regulated E-cadherin with tumour
progression and poor prognosis in gastric cancer. Histopathology.
52:560–568. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wu Y, Yamada S, Izumi H, Li Z, Shimajiri
S, Wang KY, Liu YP, Kohno K and Sasaguri Y: Strong YB-1 expression
is associated with liver metastasis progression and predicts
shorter disease-free survival in advanced gastric cancer. J Surg
Oncol. 105:724–730. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kim MA, Lee HS, Lee HE, Kim JH, Yang HK
and Kim WH: Prognostic importance of epithelial-mesenchymal
transition-related protein expression in gastric carcinoma.
Histopathology. 54:442–451. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang ZS, Shen Y, Li X, Zhou CZ, Wen YG,
Jin YB and Li JK: Significance and prognostic value of Gli-1 and
Snail/E-cadherin expression in progressive gastric cancer. Tumour
Biol. 35:1357–1363. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yang Y, Zhang J, Yan Y, Cai H, Li M, Sun
K, Wang J, Liu X, Wang J and Duan X: Low expression of Rap1GAP is
associated with epithelial-mesenchymal transition (EMT) and poor
prognosis in gastric cancer. Oncotarget. 8:8057–8068.
2017.PubMed/NCBI
|
